

09 Aug 2021 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: AstraZeneca looks to return to normality; Bayer's hopes for Kerendia; Novartis's plans for a new version of Zolgensma; Arcturus benefits from mRNA interest; and AbbVie changes tack in Alzheimer's.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 6 August 2021, including: [AstraZeneca PLC](#) looks to return to normality; [Bayer AG](#)'s hopes for Kerendia; [Novartis AG](#)'s plans for a new version of Zolgensma; [Arcturus Therapeutics Ltd.](#) benefits from mRNA interest; and [AbbVie Inc.](#) changes tack in Alzheimer's.

These and all other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Back To The Day Job? AstraZeneca's Pangalos Looks Ahead To A Post-Pandemic Pipeline](#)" - Scrip, 3 Aug, 2021.)

(Also see "[Bayer Backs Kerendia To Be A Blockbuster](#)" - Scrip, 5 Aug, 2021.)

(Also see "[Novartis Can Again Pursue Bigger Zolgensma Market After FDA Lifts OAV-101 Hold](#)" - Scrip, 3 Aug, 2021.)

(Also see "[Arcturus Leaps On COVID-19 Trials And Investor Interest In mRNA](#)" - Scrip, 4 Aug, 2021.)

(Also see "[\*AbbVie To Switch Track In Alzheimer's From Tau To Beta-Amyloid\*](#)" - Scrip, 30 Jul, 2021.)

[\*Click here to explore this interactive content online\*](#) ✎